Possibilities of metabolic surgery for the treatment of type 2 diabetes mellitus in patients with grade 1 alimentary obesity
https://doi.org/10.14341/DM9292
Abstract
Many studies have demonstrated the high effectiveness of bariatric surgery in patients with grade 2–3 obesity and type 2 diabetes mellitus. Currently, surgery is one of the most effective ways to decrease body mass, to maintain long-term weight loss and to manage type 2 diabetes mellitus. Particular interest has been generated by the strong influence of bariatric surgical interventions on the disruption of carbohydrate metabolism in patients who undergo surgery. This change leads to an improvement in the course of type 2 diabetes mellitus as well as its full remission. This review presents information on the mechanisms that are needed to improve glycaemic control in patients with obesity even after bariatric surgery. This review also contains a comparative analysis of how various surgical interventions influence the course of diabetes, the reasons for postbariatric glycaemia and predictors of the effectiveness of bariatric surgeries in terms of metabolic control in patients with type 2 diabetes mellitus.
Until recently, the primary focus of the studies by bariatric surgeons was on patients with grade 2–3 obesity and type 2 diabetes mellitus. However, in this review, special attention is given to the patients with a body mass index that ranges from 30 to 35 kg/m. Gained experience of the bariatric surgeons leads to high effectiveness with respect to the influence on the course of diabetes in patients with grade 1 obesity, which allows us to significantly expand the range of patients who should be recommended for this surgery. In addition, some information concerning surgical and metabolic complications of bariatric surgical intervention is provided, which allows us to seriously consider this treatment.
About the Authors
Vladimir V. SalukhovS.M. Kirov Military Medical Academy
Russian Federation
Head of the 1st (Clinic of therapy for postgraduate course)
Nikita S. Ilinskii
S.M. Kirov Military Medical Academy
Russian Federation
resedent in therapy
Evgenii V. Vasil'ev
City Hospital №. 40
Russian Federation
endocrinologist
Ruslan T. Sardinov
S.M. Kirov Military Medical Academy
Russian Federation
Associate professor
Dmitrii V. Gladyshev
City Hospital №. 40
Russian Federation
Head in surgery
References
1. International Diabetes Federation. IDF Diabetes Atlas. 8th ed. International Diabetes Federation; 2017.
2. Diabetes Prevention Program Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677-1686. doi: 10.1016/S0140-6736(09)61457-4
3. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-1486. doi: 10.2337/dc10-2415
4. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724-1737. doi: 10.1001/jama.292.14.1724
5. Яшков Ю.И. Возможности коррекции нарушений углеводного обмена при сахарном диабете 2 типа с применением бариатрических операций // Сахарный диабет. – 2000. – Т. 3. – №2. – С. 26–29. [Yashkov YI. Vozmozhnosti korrektsii narusheniy uglevodnogo obmena pri sakharnom diabete 2 tipa s primeneniem bariatricheskikh operatsiy. Diabetes Mellitus. 2000;3(2):26-29. (In Russ.)] doi: 10.14341/2072-0351-5883
6. Pories WJ, Swanson MS, MacDonald KG, et al. Who Would Have Thought It? An Operation Proves to Be the Most Effective Therapy for Adult-Onset Diabetes Mellitus. Ann Surg. 1995;222(3):339-352. doi: 10.1097/00000658-199509000-00011
7. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741-752. doi: 10.1056/NEJMoa066254
8. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238(4):467-484; discussion 484-465. doi: 10.1097/01.sla.0000089851.41115.1b
9. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. – 8-й выпуск // Сахарный диабет. – 2017. – Т. 20. – №1S. – C. 1-121. [Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition. Diabetes Mellitus. 2017;20(1S):1-121. (In Russ.)] doi: 10.14341/DM20171S8
10. Introduction. Diabetes Care. 2017;40(Suppl 1):S1-S2. doi: 10.2337/dc17-S001
11. Anderwald CH, Tura A, Promintzer-Schifferl M, et al. Alterations in gastrointestinal, endocrine, and metabolic processes after bariatric Roux-en-Y gastric bypass surgery. Diabetes Care. 2012;35(12):2580-2587. doi: 10.2337/dc12-0197
12. Bradley D, Conte C, Mittendorfer B, et al. Gastric bypass and banding equally improve insulin sensitivity and beta cell function. J Clin Invest. 2012;122(12):4667-4674. doi: 10.1172/JCI64895
13. Laferrere B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(7):2479-2485. doi: 10.1210/jc.2007-2851
14. Mason EE. The mechanisms of surgical treatment of type 2 diabetes. Obes Surg. 2005;15(4):459-461. doi: 10.1381/0960892053723330
15. Tsoli M, Chronaiou A, Kehagias I, et al. Hormone changes and diabetes resolution after biliopancreatic diversion and laparoscopic sleeve gastrectomy: a comparative prospective study. Surg Obes Relat Dis. 2013;9(5):667-677. doi: 10.1016/j.soard.2012.12.006
16. Bose M, Machineni S, Olivan B, et al. Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. Obesity (Silver Spring). 2010;18(6):1085-1091. doi: 10.1038/oby.2009.473
17. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002;418(6898):650-654. doi: 10.1038/nature02666
18. Wynne K, Park AJ, Small CJ, et al. Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects: A Double-Blind, Randomized, Controlled Trial. Diabetes. 2005;54(8):2390-2395. doi: 10.2337/diabetes.54.8.2390
19. Salinari S, Debard C, Bertuzzi A, et al. Jejunal proteins secreted by db/db mice or insulin-resistant humans impair the insulin signaling and determine insulin resistance. PLoS One. 2013;8(2):e56258. doi: 10.1371/journal.pone.0056258
20. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244(5):741-749. doi: 10.1097/01.sla.0000224726.61448.1b
21. Яшков Ю.И., Ершова Е.В. Эффективность бариатрических операций при СД 2-го типа. В кн.: Морбидное ожирение. / Под ред. Дедова И.И. – М.: Медицинское информационное агентство; 2014. – С. 392–409. [Yashkov YI, Ershova EV. Effektivnost' bariatricheskikh operatsiy pri SD 2-go tipa. In: Dedov II, editor. Morbidnoe ozhirenie. Moscow; 2014. p. 392–409. (In Russ.)]
22. Roux CWl, Aylwin SJB, Batterham RL, et al. Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters. Ann Surg. 2006;243(1):108-114. doi: 10.1097/01.sla.0000183349.16877.84
23. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23(5):599-622. doi: 10.1210/er.2001-0039
24. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23(2):201-229. doi: 10.1210/edrv.23.2.0461
25. Bojsen-Moller KN, Dirksen C, Jorgensen NB, et al. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes. 2014;63(5):1725-1737. doi: 10.2337/db13-1307
26. Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol. 2014;2(2):152-164. doi: 10.1016/s2213-8587(13)70218-3
27. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;336(6086):1262-1267. doi: 10.1126/science.1223813
28. Zhang H, DiBaise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A. 2009;106(7):2365-2370. doi: 10.1073/pnas.0812600106
29. Patti ME, Houten SM, Bianco AC, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring). 2009;17(9):1671-1677. doi: 10.1038/oby.2009.102
30. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10(3):167-177. doi: 10.1016/j.cmet.2009.08.001
31. Wu T, Bound MJ, Standfield SD, et al. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. Diabetes Obes Metab. 2013;15(5):474-477. doi: 10.1111/dom.12043
32. Raveendran AV, Shiji PV, Pappachan JM. Role Of Bariatric Surgery In Type 2 Diabetes. BMH Med. J. 2017;4(1):6–16.
33. Itariu BK, Zeyda M, Prager G, Stulnig TM. Insulin-like growth factor 1 predicts post-load hypoglycemia following bariatric surgery: a prospective cohort study. PLoS One. 2014;9(4):e94613. doi: 10.1371/journal.pone.0094613
34. Rubino F, Kaplan LM, Schauer PR, et al. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg. 2010;251(3):399-405. doi: 10.1097/SLA.0b013e3181be34e7
35. Dixon JB, Zimmet P, Alberti KG, et al. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabet Med. 2011;28(6):628-642. doi: 10.1111/j.1464-5491.2011.03306.x
36. Hall TC, Pellen MG, Sedman PC, Jain PK. Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity. Obes Surg. 2010;20(9):1245-1250. doi: 10.1007/s11695-010-0198-8
37. Lee WJ, Chong K, Ser KH, et al. C-peptide predicts the remission of type 2 diabetes after bariatric surgery. Obes Surg. 2012;22(2):293-298. doi: 10.1007/s11695-011-0565-0
38. Kassem MA, Durda MA, Stoicea N, et al. The Impact of Bariatric Surgery on Type 2 Diabetes Mellitus and the Management of Hypoglycemic Events. Front Endocrinol (Lausanne). 2017;8:37. doi: 10.3389/fendo.2017.00037
39. Yu H, Di J, Bao Y, et al. Visceral fat area as a new predictor of short-term diabetes remission after Roux-en-Y gastric bypass surgery in Chinese patients with a body mass index less than 35 kg/m2. Surg Obes Relat Dis. 2015;11(1):6-11. doi: 10.1016/j.soard.2014.06.019
40. Cohen RV, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35(7):1420-1428. doi: 10.2337/dc11-2289
41. Shimizu H, Timratana P, Schauer PR, Rogula T. Review of Metabolic Surgery for Type 2 Diabetes in Patients with a BMI < 35 kg/m(2). J Obes. 2012;2012:147256. doi: 10.1155/2012/147256
42. Demaria EJ, Winegar DA, Pate VW, et al. Early postoperative outcomes of metabolic surgery to treat diabetes from sites participating in the ASMBS bariatric surgery center of excellence program as reported in the Bariatric Outcomes Longitudinal Database. Ann Surg. 2010;252(3):559-566; discussion 566-557. doi: 10.1097/SLA.0b013e3181f2aed0
43. Rubino F, Nathan DM, Eckel RH, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations. Obes Surg. 2017;27(1):2-21. doi: 10.1007/s11695-016-2457-9
44. Lebovitz HE. Science, clinical outcomes and the popularization of diabetes surgery. Curr Opin Endocrinol Diabetes Obes. 2012;19(5):359-366. doi: 10.1097/MED.0b013e328358301f
45. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683-2693. doi: 10.1056/NEJMoa035622
46. Chikunguwo SM, Wolfe LG, Dodson P, et al. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2010;6(3):254-259. doi: 10.1016/j.soard.2009.11.003
47. DiGiorgi M, Rosen DJ, Choi JJ, et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis. 2010;6(3):249-253. doi: 10.1016/j.soard.2009.09.019
48. Ramos Y, Bersoux S, Roust LR, Chang YH. Type 2 diabetes reemergence post-gastric bypass surgery. In: Proceedings of the Endocrine Society's 94th Annual Meeting and Expo; 2012 June 23–26; Houston.
49. Arterburn DE, Courcoulas AP. Bariatric surgery for obesity and metabolic conditions in adults. BMJ. 2014;349:g3961. doi: 10.1136/bmj.g3961
50. Chang SH, Stoll CR, Song J, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149(3):275-287. doi: 10.1001/jamasurg.2013.3654
51. Tack J, Arts J, Caenepeel P, et al. Pathophysiology, diagnosis and management of postoperative dumping syndrome. Nat Rev Gastroenterol Hepatol. 2009;6(10):583-590. doi: 10.1038/nrgastro.2009.148
52. Alvarez GC, Faria EN, Beck M, et al. Laparoscopic spleen-preserving distal pancreatectomy as treatment for nesidioblastosis after gastric bypass surgery. Obes Surg. 2007;17(4):550-552. doi: 10.1007/s11695-007-9096-0
53. Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347:f5934. doi: 10.1136/bmj.f5934
54. Zuegel NP, Lang RA, Huttl TP, et al. Complications and outcome after laparoscopic bariatric surgery: LAGB versus LRYGB. Langenbecks Arch Surg. 2012;397(8):1235-1241. doi: 10.1007/s00423-012-0945-5
55. Gletsu-Miller N, Wright BN. Mineral malnutrition following bariatric surgery. Adv Nutr. 2013;4(5):506-517. doi: 10.3945/an.113.004341
56. Christou NV, Sampalis JS, Liberman M, et al. Surgery Decreases Long-term Mortality, Morbidity, and Health Care Use in Morbidly Obese Patients. Ann Surg. 2004;240(3):416-424. doi: 10.1097/01.sla.0000137343.63376.19
57. Васильев Е.В., Вологжанин Д.А., Салухов В.В., и др. Нарушения сна и качество жизни в отдаленном периоде у пациентов, перенесших бариатрические оперативные // Медицинский академический журнал. – 2016. – Т. 16. – №4. – С. 20–21. [Vasil'ev EV, Vologzhanin DA, Salukhov VV, et al. Narusheniya sna i kachestvo zhizni v otdalennom periode u patsientov, perenesshikh bariatricheskie operativnye. Med Akad Z. 2016;16(4):20–21. (In Russ.)]
58. Muller-Stich BP, Fischer L, Kenngott HG, et al. Gastric bypass leads to improvement of diabetic neuropathy independent of glucose normalization--results of a prospective cohort study (DiaSurg 1 study). Ann Surg. 2013;258(5):760-765; discussion 765-766. doi: 10.1097/SLA.0b013e3182a618b2
59. Brethauer SA, Aminian A, Romero-Talamas H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258(4):628-636; discussion 636-627. doi: 10.1097/SLA.0b013e3182a5034b
60. Cheung D, Switzer NJ, Ehmann D, et al. The Impact of Bariatric Surgery on Diabetic Retinopathy: A Systematic Review and Meta-Analysis. Obes Surg. 2015;25(9):1604-1609. doi: 10.1007/s11695-014-1539-9
61. Murphy R, Jiang Y, Booth M, et al. Progression of diabetic retinopathy after bariatric surgery. Diabet Med. 2015;32(9):1212-1220. doi: 10.1111/dme.12727
62. Birkmeyer JD, Finks JF, O'Reilly A, et al. Surgical skill and complication rates after bariatric surgery. N Engl J Med. 2013;369(15):1434-1442. doi: 10.1056/NEJMsa1300625
Supplementary files
|
1. 1 | |
Subject | ||
Type | Исследовательские инструменты | |
View
(26KB)
|
Indexing metadata ▾ |
|
2. 2 | |
Subject | ||
Type | Исследовательские инструменты | |
View
(23KB)
|
Indexing metadata ▾ |
|
3. 3 | |
Subject | ||
Type | Исследовательские инструменты | |
View
(24KB)
|
Indexing metadata ▾ |
|
4. 4 | |
Subject | ||
Type | Исследовательские инструменты | |
View
(28KB)
|
Indexing metadata ▾ |
|
5. 5 | |
Subject | ||
Type | Исследовательские инструменты | |
View
(33KB)
|
Indexing metadata ▾ |
|
6. Fig. 1. Chronology of the development of the main processes after DU, determining the probability of remission of CD2 [24]. | |
Subject | ||
Type | Исследовательские инструменты | |
View
(73KB)
|
Indexing metadata ▾ |
|
7. Fig. 2. Basic mechanisms of DU, leading to remission of CD2 / improved glycemic control in patients (adapted [32]) | |
Subject | ||
Type | Исследовательские инструменты | |
View
(111KB)
|
Indexing metadata ▾ |
|
8. Fig. 3. Algorithm for choosing treatment in a patient with diabetes, depending on BMI and glycemic control [41] (in Asian-born people, the BMI decreases by 2.5 kg / m2) | |
Subject | ||
Type | Исследовательские инструменты | |
View
(82KB)
|
Indexing metadata ▾ |
Review
For citations:
Salukhov V.V., Ilinskii N.S., Vasil'ev E.V., Sardinov R.T., Gladyshev D.V. Possibilities of metabolic surgery for the treatment of type 2 diabetes mellitus in patients with grade 1 alimentary obesity. Diabetes mellitus. 2018;21(1):15-25. (In Russ.) https://doi.org/10.14341/DM9292

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).